For decades, birth control has largely been shaped around the female body. Women have had access to pills, implants, injections, and intrauterine devices, while men have had far fewer options beyond condoms or permanent procedures such as vasectomy.
A new Cornell University study is challenging that imbalance by showing a possible path toward temporary male fertility control. But the most important part of the research is not simply that scientists stopped sperm production.
It’s that they were able to restart it.
Published in the Proceedings of the National Academy of Sciences on April 7, 2026, the study showed that researchers could temporarily interrupt sperm development in male mice and later restore fertility, including the ability to produce healthy offspring.
The findings don’t mean a male birth control pill is coming soon. The compound used in the experiment, (+)-JQ1, is not suitable for human contraception because it has neurological side-effect concerns and affects proteins beyond the intended target.
Instead, the research represents a major scientific step toward answering one of the biggest questions in male contraception:
Can fertility be temporarily paused without damaging the ability to become a father in the future?
Scientists Targeted the Process Behind Sperm Production
The Cornell research focused on a protein called BRDT, a testis-specific protein that plays an important role in sperm development.
During normal reproduction, BRDT helps regulate gene activity and chromosome organization as sperm cells mature. Researchers wanted to determine whether temporarily blocking this process could stop sperm production without permanently harming the reproductive system.
To test the idea, male mice were treated with (+)-JQ1 for three weeks.
The compound disrupted meiotic prophase I, a critical stage of cell division required for sperm formation. After treatment, researchers observed a loss of post-meiotic germ cells, and the treated mice stopped producing sperm.
The key question came after the treatment ended.
Scientists needed to know whether the reproductive system had been permanently damaged or whether it could rebuild itself.
The Recovery Took Weeks, But Some Biological Processes Took Months
Researchers found that several reproductive markers returned within approximately six weeks after treatment stopped. During this period, the mice recovered normal testicular structure, germ-cell composition, and indicators linked to meiotic development.
However, the recovery process was not complete in every measurement at that stage.
The study found that some of the most detailed genetic processes, including meiotic crossover measurements and gene-transcription programs, returned fully to normal only after approximately 30 weeks.
Fertility recovery is more complicated than simply producing sperm again. Scientists must also determine whether sperm development resumes normally, whether genetic processes are restored, and whether future offspring remain healthy.
The Biggest Test Was Whether the Mice Could Become Fathers Again
Researchers did not only examine sperm production. They tested whether recovered male mice could successfully reproduce.
The results were significant: recovered mice produced healthy offspring, and those offspring later showed normal fertility.
Paula Cohen, a Cornell professor of genetics and senior author of the study, said the results addressed one of the biggest concerns in male contraceptive research.
“Our study shows that mostly we recover normal meiosis and complete sperm function, and more importantly, that the offspring are completely normal,” Cohen said.
The researchers specifically designed the approach to avoid damaging spermatogonial stem cells, the cells responsible for continuously generating sperm.
“We didn’t want to impact the spermatogonial stem cells, because if you kill those, a man will never become fertile again,” Cohen said.
Protecting these stem cells is central to the idea of reversible male contraception.
Why This Is Not Yet a Male Birth Control Drug
Although the findings have attracted attention, (+)-JQ1 itself is not a future contraceptive product.
The compound is considered a proof-of-principle research tool rather than a medication ready for humans.
One challenge is that JQ1 does not only affect BRDT. It belongs to a class of compounds called BET inhibitors, which can also interact with related proteins such as BRD2, BRD3, and BRD4.
Those broader effects create safety concerns.
Cornell researchers have stated that neurological side effects make JQ1 unsuitable as a final male contraceptive.
Save this article
Enter your email address and we'll send it straight to your inbox.
The next challenge for scientists is creating a compound that can achieve the same fertility-control effect while targeting BRDT more precisely.
In other words, researchers may have found a possible biological pathway, but they have not yet found the finished product.
A Future Male Contraceptive Could Change How Couples Share Responsibility
If researchers eventually develop a safe and effective male contraceptive, the impact could extend beyond medicine.
The change would involve who participates directly in preventing pregnancy.
Current contraceptive options mean women often carry much of the physical responsibility. A successful male method could create another option for couples who want shared control over fertility decisions.
Survey data shows measurable interest, although acceptance depends heavily on safety, cost, effectiveness, and trust.
A 2023 U.S. survey of 2,060 cisgender men found that 75% said they would be willing to use a novel male contraceptive method.
Another U.S. community survey of 187 non-sterilized men ages 18 to 45 with recent pregnancy risk found that 72% were very willing to use at least one new male contraceptive option.
The preferred methods varied. In that survey, 62% said they were very willing to use a pill, 52.2% said they were very willing to use a gel, while 24.2% said they were very willing to use vas occlusion procedures.
However, concerns about cost and side effects remained significant.
Among participants in the same U.S. survey, 76.5% said high cost would reduce their willingness, while 66.3% said side effects would reduce their willingness.
Women have also expressed interest in male contraception, particularly when it creates shared responsibility.
A 2026 U.S. survey of women of reproductive age found that 67.5% were interested in a partner using a new male contraceptive method. Among interested women, 72.5% believed their partner would be willing to try one.
The most common reasons women supported male contraception were:
- 60.6% said shared responsibility was a reason
- 42.2% said it could provide additional protection alongside existing contraception
- 36% said avoiding side effects from female contraception was a reason
Trust, however, remains a major factor.
An Ipsos survey found that 80% of women said they would trust a long-term partner to use a male pill or injection, but only 30% said they would trust a short-term partner to do the same.
Related: 8 Alarming Reasons More Adult Children Are Cutting Off Their Parents
The Road From Mouse Research to Human Birth Control Is Still Long
The Cornell findings are promising, but they remain an early scientific discovery.
The study involved mice, not humans. It does not show whether the same approach will safely work in men, what dosage would be required, how often treatment could be repeated, or whether every user would recover fertility in the same way.
Researchers would need to complete multiple stages of human testing before any similar method could become available.
Scientists would need evidence showing:
- reliable pregnancy prevention,
- predictable fertility recovery,
- long-term safety,
- no harmful effects on sperm DNA,
- no serious effects on mood, sexual function, or overall health.
Other male contraceptive approaches are also being studied.
YCT-529, a nonhormonal oral drug that targets retinoic acid signaling, is currently in human research. ADAM, a hydrogel-based method designed to temporarily block sperm transport, is also being evaluated.
But as of now, no reversible male contraceptive has received regulatory approval.
The Cornell study does not mark the arrival of male birth control.
It marks evidence that scientists may one day be able to control fertility temporarily without making fatherhood a permanent decision.
More Articles:
- 10 Hidden Struggles Husbands Face When Raising a Child That Isn’t Theirs
- FDA Posts Nationwide Recall of Cetirizine Allergy Tablets Over Ranitidine Contamination Risk
- Fewer Children, Rising Debt, and Uncertainty: Why the West Is Slowly Declining
- If Your Child Watches Kid Influencers, You Need to Read This
